Request Demo
Last update 15 May 2025
Urokinase (Techpool Bio-Pharma)
Last update 15 May 2025
Overview
Basic Info
Drug Type Enzyme |
Synonyms 洛欣 |
Target- |
Action- |
Mechanism Enzyme replacements |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhaseApproved |
First Approval Date China (16 Nov 2005), |
Regulation- |
Login to view timeline
Structure/Sequence
Sequence Code 1191632823
Source: *****
Related
4
Clinical Trials associated with Urokinase (Techpool Bio-Pharma)NCT06085378
Efficacy and Safety of Urinary Kallidinogenase in the Treatment of Acute Ischemic Stroke Combined With Type 2 Diabetes Mellitus (TK-SEEK): a Prospective, Multicenter, Randomized, Double-blind, Placebo-parallel Controlled Study
NCT02562183
The Study to Reevaluate the Safety and Efficacy of Human Urinary Kallikrein
JPRN-UMIN000013174
The effect of kallidinogenase for the retina thickness and visual acuity etc.after intravitreal bevacizumab for diabetic macula edema. - The effect of kallidinogenase for diabetic macula edema after intravitreal bevacizumab.
100 Clinical Results associated with Urokinase (Techpool Bio-Pharma)
Login to view more data
100 Translational Medicine associated with Urokinase (Techpool Bio-Pharma)
Login to view more data
100 Patents (Medical) associated with Urokinase (Techpool Bio-Pharma)
Login to view more data
100 Deals associated with Urokinase (Techpool Bio-Pharma)
Login to view more data
R&D Status
10 top approved records. to view more data
Login
| Indication | Country/Location | Organization | Date |
|---|---|---|---|
| Intracranial Embolism | China | 16 Nov 2005 | |
| Myocardial Infarction | China | 16 Nov 2005 | |
| Pulmonary Embolism | China | 16 Nov 2005 | |
| Retinal Artery Occlusion | China | 16 Nov 2005 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Not Applicable | 21 | Patients with kallidinogenase | swnxtitsuw(hrqthelqlh) = dwqcicurva dpkrevsfxm (sfhqrpucpe ) | Positive | 17 Nov 2013 | ||
swnxtitsuw(hrqthelqlh) = gaabbkvrft dpkrevsfxm (sfhqrpucpe ) |
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Biosimilar
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free